Evidence map›Paper›PMID 38247866›Full record

ReviewCells2024

Targeted Protein Degradation Systems: Controlling Protein Stability Using E3 Ubiquitin Ligases in Eukaryotic Species.

Yoshitaka Ogawa, Taisei P Ueda, Keisuke Obara, Kohei Nishimura, Takumi Kamura

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yoshitaka OgawaDepartment of Biological Science, Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya 464-8601, Japan.
Taisei P UedaDepartment of Biological Science, Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya 464-8601, Japan.
Keisuke ObaraDepartment of Biological Science, Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya 464-8601, Japan.ORCID 0000-0002-2441-0907
Kohei NishimuraDepartment of Biological Science, Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya 464-8601, Japan.
Takumi KamuraDepartment of Biological Science, Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya 464-8601, Japan.
Nagoya University · JP

Funding

Japan Society for the Promotion of Science JP19K06611, JP20K21423, JP22K05558, JP20H03208Japan Society for the Promotion of Science JP23H02433
6 · The paper itself

Abstract

This review explores various methods for modulating protein stability to achieve target protein degradation, which is a crucial aspect in the study of biological processes and drug design. Thirty years have passed since the introduction of heat-inducible degron cells utilizing the N-end rule, and methods for controlling protein stability using the ubiquitin-proteasome system have moved from academia to industry. This review covers protein stability control methods, from the early days to recent advancements, and discusses the evolution of techniques in this field. This review also addresses the challenges and future directions of protein stability control techniques by tracing their development from the inception of protein stability control methods to the present day.

Indexed as

Proteasome Endopeptidase ComplexUbiquitin-Protein LigasesCytoplasmProtein StabilityProteolysisProteasome Endopeptidase ComplexUbiquitin-Protein LigasesE3 ubiquitin ligasePROTACstarget protein degradationubiquitinubiquitin proteasome pathway

Identifiers

PMID38247866
PMCPMC10814424
OpenAlexW4390944540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.